Haverford Healthcare Advisors is pleased to announce its role as exclusive financial advisor to Nebraska LabLinc, L.L.C. (“NLL”) in connection with the sale of NLL to Laboratory Corporation of America Holdings (LH: NYSE). Haverford initiated this transaction on behalf of NLL.
Nebraska LabLinc, L.L.C. (“NLL”) is a full-service, pathologist-owned, independent clinical laboratory located in Lincoln, Nebraska which serves clients in Eastern Nebraska. With a significant testing facility, along with two busy patient service centers, a staff of eleven highly-skilled and experienced pathologists, a staff of over 180 full-time-equivalent employees comprised of medical technologists, phlebotomists, couriers, sales representatives and other staff, NLL represents a substantial platform to serve the clinical and anatomic pathology testing needs of the region.
Laboratory Corporation of America Holdings, an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. LabCorp is a pioneer in commercializing new diagnostic technologies and is improving people’s health by delivering the combination of world-class diagnostics, drug development services and technology-enabled solutions. With net revenue in excess of $8.5 billion in 2015 and more than 50,000 employees in approximately 60 countries, LabCorp offers innovative solutions to healthcare stakeholders. LabCorp clients include physicians, patients and consumers, biopharmaceutical companies, government agencies, managed care organizations, hospitals, and clinical labs.